Common Contracts
3 similar Securities Purchase Agreement contracts by Cidara Therapeutics, Inc., Mri Interventions, Inc., OncoCyte Corp
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2019 • Mri Interventions, Inc. • Surgical & medical instruments & apparatus • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of May 9, 2019, by and among MRI Interventions, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 29th, 2018 • OncoCyte Corp • In vitro & in vivo diagnostic substances • California
This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2018, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 20th, 2017 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 19, 2017 (the “Effective Date”) by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Schedule I hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 11 hereof.
